GT 389-255
GT 389-255 Uses, Dosage, Side Effects, Food Interaction and all others data.
Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.
| Trade Name | GT 389-255 |
| Generic | GT 389-255 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in obesity.
How GT 389-255 works
GT 389-255 is a novel conjugate of a proprietary pancreatic lipase inhibitor and a fatbinding hydrogel polymer for the treatment of obesity. GT 389-255 is a novel conjugate of a proprietary pancreatic lipase inhibitor and a fat binding hydrogel polymer for the treatment of obesity. It acts within the gastro-intestinal tract to prevent fat digestion and is expected to inhibit > 30% of fat absorption. The novel conjugate is expected to have fewer side-effects than currently marketed therapies. The currently marketed pancreatic lipase inhibitor Orlistat, is associated with oily incontinence, caused by mal-absorbed triglycerides. GT 389-255 is expected to have minimal systemic exposure. Less than 1% of the lipase inhibitor is absorbed and the fat binding polymer is not absorbed.
Innovators Monograph
You find simplified version here GT 389-255
